Applications of 1-N-Boc-3-Azetidinecarboxylic Acid in Industrial Manufacturing

1-N-Boc-3-Azetidinecarboxylic Acid plays a critical role in the synthesis of specialty chemicals for pharmaceutical intermediates, active pharmaceutical ingredients, peptide drugs, chiral ligand manufacturing, fine chemical processes, and crop protection compounds. Below, we present the principal industrial applications with focus on compliance, usage ratio, process integration, and final downstream products.

1. Pharmaceutical Intermediate for β-Lactam Antibiotics

This material serves as a key protected azetidine intermediate in the synthesis of new β-lactam antibiotic candidates, where its steric and chemical properties support the construction of strained ring systems. Manufacturers employ this compound in multistep synthesis to achieve backbone rigidity in advanced pharma intermediates, which enhances target selectivity and stability during subsequent reactions.

Industry compliance standards

• ICH Q7 Good Manufacturing Practice for Active Pharmaceutical Ingredients
• European Pharmacopoeia (Ph. Eur.) monographs for API intermediates
• 21 CFR Part 211 US FDA GMP for finished pharmaceuticals
• Chinese Pharmacopoeia standards for pharmaceutical synthesis

Typical usage ratio

• Employed at 0.2 to 0.6 molar equivalents relative to β-lactam ring precursors, with adjustment based on desired substitution pattern and targeted intermediate yield

Downstream process integration

• Introduced during the early cyclization stage after amide coupling and deprotection steps
• Requires Boc-group removal under acidic conditions before further elaboration of the ring system
• Subjected to strict in-process controls for purity and residual solvent analysis

Final product types

• β-lactam antibiotic APIs (e.g., cephalosporin derivatives, carbapenem building blocks)
• Advanced pharmaceutical intermediates for research and clinical development

2. Protected Azetidine Building Block in Peptide Synthesis

1-N-Boc-3-Azetidinecarboxylic Acid is widely used as an unnatural amino acid component in solid-phase and solution-phase peptide synthesis, aiding structural modification for improved stability or activity. The Boc-protected azetidine unit introduces conformational constraints and increases peptide diversity, directly integrating into peptide chain elongation protocols on industrial peptide synthesizers.

Industry compliance standards

• US FDA 21 CFR Part 210 and 211 GMP requirements for pharmaceutical peptides
• European Medicines Agency (EMA) guidelines for peptide APIs
• Japanese Pharmacopoeia (JP) and European Pharmacopoeia peptide substance monographs
• ISO 9001:2015 Quality Management Systems in peptide production facilities

Typical usage ratio

• Used at 0.9 to 1.1 equivalents per corresponding peptide coupling cycle, controlled based on resin loading and chain length requirements

Downstream process integration

• Loaded onto solid phase resin during the amino acid elongation cycle after standard Fmoc deprotection
• Requires selective Boc-deprotection prior to final chain cleavage from resin
• Purity and structural integrity assessed by HPLC and mass spectrometry in-line with each batch

Final product types

• Peptide therapeutics for metabolic and oncology applications
• Peptide-based research tools and diagnostic agents

3. Intermediate for Chiral Ligand and Catalyst Synthesis

1-N-Boc-3-Azetidinecarboxylic Acid provides a strained cyclic structure and defined stereochemistry, making it valuable for the preparation of chiral ligands and auxiliaries in enantioselective catalysis. It serves as a precursor for nitrogen-containing ligands used in asymmetric hydrogenation and cross-coupling reactions in industrial-scale fine chemical production and custom synthesis.

Industry compliance standards

• REACH Regulation (EC) No 1907/2006 for registration and safe handling in the EU
• Toxic Substances Control Act (TSCA) compliance for chemical intermediates in the US
• ISO 14001 Environmental Management System certification (for facilities using chiral catalysts in manufacturing)
• GMP for Starting Materials for Stereochemical Synthesis (as referenced in relevant regulatory submissions)

Typical usage ratio

• Employed at 0.5 to 1.0 equivalents per chiral group in ligand synthesis, adjusted according to target ligand backbone structure and desired selectivity profile

Downstream process integration

• Deprotection of the Boc group conducted before coupling with other ligand frameworks using standard amide bond formation or reductive amination
• Used in batch synthesis reactors under inert atmosphere to preserve stereochemical integrity
• Integrated QC checks for enantiopurity and residual Boc contamination prior to catalyst implementation

Final product types

• Chiral phosphine ligands
• Chiral bis(azetidine) compounds for fine chemical and API manufacturing
• Auxiliaries for asymmetric hydrogenation and Suzuki-Miyaura coupling catalysts

4. Fine Chemical Synthesis for CNS-Active Drug Candidates

The azetidine ring system, protected with a Boc group, serves as a core intermediate for synthesizing central nervous system (CNS) active drug candidate scaffolds, particularly in the preparation of azetidine derivatives with enhanced bioavailability. Fine chemical companies use this raw material in targeted batch processes aimed at building heterocyclic frameworks relevant for CNS pharmacophores under controlled, GMP-aligned conditions.

Industry compliance standards

• ICH Q11 Development and Manufacture of Drug Substances
• US Drug Enforcement Administration (DEA) controlled substances handling (if applicable in CNS drug synthesis)
• Good Laboratory Practice (GLP) for non-clinical safety studies
• ISO 9001 standard operating procedures for specialty synthesis

Typical usage ratio

• Applied at 0.8 to 1.2 molar equivalents as determined by the synthetic route and target CNS scaffold complexity

Downstream process integration

• Employed in early-stage ring-incorporation steps after amide or urea formation
• Subsequent removal of Boc group enables diversification on the azetidine nitrogen
• Process involves stepwise impurity profiling after each ring modification step

Final product types

• CNS-active small molecule API candidates
• Advanced intermediates for psychotropic and neuroprotective compounds

5. Precursor for Crop Protection Compound Synthesis

This material functions as a valuable starting point in the preparation of novel azetidine-based crop protection agents, where the role of the Boc group enables advanced derivatization protocols in agchem research pipelines. Its chemical stability supports preparative scale synthesis of azetidine herbicide and fungicide intermediates, meeting stringent agricultural chemical safety requirements.

Industry compliance standards

• FAO/WHO Specifications and Evaluations for Agricultural Pesticides
• OECD principles of Good Laboratory Practice for chemical safety
• ISO 17025 laboratory testing compliance
• REACH guidance for chemical registration and documentation

Typical usage ratio

• Introduced at 0.3 to 0.7 equivalents per crop protection target molecule, ratios are determined by type of heterocycle and downstream reactivity requirements

Downstream process integration

• Fed into cyclization and functionalization processes as the azetidine core unit, following Boc removal on pilot plant scale reactors
• In-process checks performed for NMR and GC purity on all intermediates before downstream derivatization

Final product types

• Azetidine-based herbicide and fungicide active ingredients
• Formulated crop protection research compounds for regulatory submission and field trial use